Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple vaccine slash COPD attacks?

NCT ID NCT07508644

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of the RSV vaccine (Arexvy) can reduce moderate-to-severe COPD flare-ups in people who have frequent attacks. Researchers will enroll 320 high-risk patients aged 50+ and follow them for one year. Half will get the vaccine plus standard care, the other half standard care alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RSV vaccine (Arexvy)
What this could lead to
If it works, this could reduce the number of serious COPD flare-ups by at least 20%, offering a new way to manage the disease.
What could go wrong
This is a Phase 4 trial, but it's open-label (no placebo), which can bias results. The 20% reduction target is modest, and the vaccine may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2027

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 50 years or older * Spirometry evidence of airflow obstruction (post-bronchodilator FEV1/FVC \<0.70) * Current or former smoker who had accrued a ≥10 pack-year smoking history * Frequent COPD exacerbator, as defined by at least ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to screening \[31,32\] * On dual LABD (LABA and LAMA) using the same inhaler/device for ≥8 weeks * Up-to-date influenza and pneumococcal vaccination received at least 1 month prior to screening Exclusion Criteria: * Coexisting significant pulmonary disease predominating the respiratory symptoms (e.g. asthma, bronchiectasis) * Life expectancy shorter than 1 year due to serious or unstable chronic illness (e.g. advanced lung cancer) * Refused to receive RSV vaccine (for the RSV group only) * Received RSV vaccine of any brand before * Immunocompromised or long-term steroid user (≥10mg/day prednisolone or equivalent for ≥2 weeks), which may affect the RSV vaccine efficacy * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine * Pregnant or lactating (females not yet menopausal must have a negative pregnancy test before receiving the RSV vaccination) * Unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD RSV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Prince of Wales Hospital

    Shatin, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.